ZeClinics’ Pick of the Week: Trending now! Luc Truyen from Janssen, Ricardo Dolmetsch from Novartis and many more talk about fighting neurodisorders.
Being in the contract research business, everyone at ZeClinics knows the importance of outsourcing and public-private partnerships in bringing new treatments forward. This is particularly true for neurological diseases, a complex field in which we are heavily involved with our Alzheimer, epilepsy and Parkinson preclinical work. Intractable cases, unmet medical needs, rising costs and incidence of neurodisorders…
With so many challenges one would need a neurology guru to know which one to tackle first! Lucky for us the guys at PhRMA invited some of them to give us their two cents.
Read all about it in their 2018 report!
Source: PhRMA
Medicines in Development for Neurological Disorders 2018 Report
Neurological disorders are a group of more than 1,000 conditions that affect the brain and nervous system. Together, these disorders impact an estimated 100 million Americans, nearly a third of the U.S. population. Although some are well known, such as Alzheimer’s disease, epilepsy, migraine headaches, multiple sclerosis and Parkinson’s disease, many are rare and affect a small number of patients. Of the more than 7,000 known rare diseases, about 360 of them are primarily neurological, including amyotrophic lateral sclerosis (ALS) and Huntington’s disease.
Today, biopharmaceutical research companies are developing 537 medicines for numerous, wide-ranging neurological disorders. There is hope on the horizon, as scientists are uncovering more about how the nervous system works at the molecular and genetic levels, driving the development of innovative treatments for several neurological disorders.
Download the report to learn more.